Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Emerging pharmacological therapies in fragile X syndrome and autism
Hidenori Yamasue
*
,
Adi Aran
, Elizabeth Berry-Kravis
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Review article
›
peer-review
24
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging pharmacological therapies in fragile X syndrome and autism'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Autism
100%
Autism Spectrum Disorder
100%
Fragile X Syndrome
100%
Pharmacological Therapy
100%
Non-syndromic
33%
Molecular Targets
22%
Cognitive Deficits
11%
Novel Therapeutics
11%
High Prevalence
11%
Cannabinoids
11%
Behavioural Syndrome
11%
Drug Development
11%
Therapeutic Agents
11%
Unmet Medical Need
11%
Social Communication
11%
Behavioral Deficits
11%
Fragile X Mental Retardation 1 (FMR1)
11%
Molecular Pathogenesis
11%
Monogenic
11%
Restricted Repetitive Behaviors
11%
Treatment Development
11%
Metabotropic Glutamate Receptor 5 (mGluR5)
11%
Targeted Treatment
11%
GABAB Receptor
11%
Autism Treatment
11%
Causal Genes
11%
Current Review
11%
Therapeutic Development
11%
Oxytocin/vasopressin
11%
Syndromic Autism
11%
Medicine and Dentistry
Drug Therapy
100%
Fragile X Syndrome
100%
Autism Spectrum Disorder
100%
Autism
100%
Pathophysiology
22%
Prevalence
11%
Targeted Therapy
11%
Oxytocin
11%
Therapeutic Agent
11%
Molecular Pathology
11%
Vasopressin
11%
Treatment Development
11%
4 Aminobutyric Acid B Receptor
11%
Cannabinoid
11%
Compulsive Behavior
11%
Metabotropic Receptor 5
11%
Neuroscience
Fragile X Syndrome
100%
Autism
100%
Autism Spectrum Disorder
100%
Drug Therapy
100%
Oxytocin
11%
Compulsive Behavior
11%
Treatment Development
11%
4 Aminobutyric Acid B Receptor
11%
Cannabinoid
11%
Vasopressin
11%
Metabotropic Glutamate Receptor 5
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Fragile X Syndrome
100%
Autism
100%
Pathophysiology
20%
Molecular Target
20%
Syndrome
10%
Prevalence
10%
Drug Development
10%
Molecular Pathology
10%
Oxytocin
10%
Vasopressin
10%
Cannabinoid
10%
4 Aminobutyric Acid B Receptor
10%
Metabotropic Receptor 5
10%